8-K: HeartSciences Extends Loan Maturity, Raises $6.7M

HeartSciences Inc. extended its loan maturity with Front Range Ventures to September 2026 and reported raising $6.7 million in gross proceeds from its Regulation A offering, alongside a $2.1 million debt-for-equity exchange.

Summary

• The maturity date of the secured promissory note with Front Range Ventures LLC (FRV) has been extended to September 30, 2026, through Amendment No. 7 to the Loan and Security Agreement.
• The original loan amount from FRV was $500,000, accruing interest at a rate of 12% per annum, compounded annually.
• Accrued unpaid interest as of September 30, 2025, is payable on or before that date, with all subsequent accrued unpaid interest due on the new maturity date of September 30, 2026.
• The company retains the discretion to repay all or part of the outstanding principal amount of the note at any time prior to the maturity date, provided each repayment is not less than $50,000 and is applied first to accrued interest, then to principal.
• As of October 1, 2025, the company has received $6.7 million in gross proceeds from its Regulation A Offering, resulting in the issuance of 1,912,383 units.
• Each unit in the Regulation A Offering consists of one share of Series D Preferred Stock and one warrant to purchase common stock at an exercise price of $5.00 per share, with a maximum offering amount of $15,000,000.
• Holders of 1,331,044 shares of Series D Preferred Stock from the offering have elected to convert these shares into 1,331,044 shares of common stock.
• A debt exchange was completed as of October 1, 2025, reducing an unsecured promissory note by $2,060,000 in principal and $45,000 in accrued interest, in exchange for 597,578 shares of the company's common stock.
• Following the Regulation A Issuance and the Debt Exchange, there are 3,069,635 shares of common stock issued and outstanding as of October 1, 2025.

Sentiment

Score: 6

Explanation: The extension of the loan maturity and successful capital raise are positive for liquidity and debt management. However, the high interest rate on the secured loan, the repeated need for extensions, and significant shareholder dilution from the debt-for-equity exchange and preferred stock conversions temper the overall positive sentiment, indicating ongoing financial challenges and a high cost of capital.

Positives

• The successful extension of the secured loan's maturity date to September 30, 2026, provides the company with additional time and financial flexibility to manage its debt obligations.
• The company has raised $6.7 million in gross proceeds from its Regulation A offering, indicating investor interest and providing capital for operations or other strategic initiatives.
• A significant debt exchange, reducing an unsecured promissory note by $2,060,000 in principal and $45,000 in accrued interest, improves the company's balance sheet by converting debt to equity and reducing future cash interest payments.

Negatives

• The need for a seventh amendment to the loan agreement suggests ongoing financial challenges or a limited ability to secure more favorable financing terms.
• The 12% annual interest rate on the secured promissory note is relatively high, indicating a higher cost of capital for the company.
• The debt-for-equity exchange and the conversion of Series D Preferred Stock into common stock from the Regulation A offering result in dilution for existing shareholders.

Risks

• Failure to make timely payments on the secured promissory note could trigger an Event of Default, leading to the acceleration of all outstanding obligations and potential foreclosure on the company's assets.
• Breach of any provision in the Loan Agreement or the Amended Note, or any material misrepresentation, constitutes an Event of Default.
• Default on other indebtedness of $10,000 or more could trigger an Event of Default.
• Bankruptcy, insolvency, dissolution, or liquidation of the company would lead to an Event of Default.
• A final judgment or order for payment exceeding $10,000 against the company, if undischarged for 10 days, constitutes an Event of Default.
• Cessation of operations by the company would trigger an Event of Default.
• The sale, conveyance, or disposition of all or substantially all assets, or a transaction resulting in a change of control (more than 50% of voting power disposed), would be an Event of Default.
• Restrictions on lending money or guaranteeing obligations without the lender's written consent could limit operational flexibility.
• The high interest rate (12% per annum) on the secured note increases the cost of capital and financial burden.
• Dilution of existing shareholders due to the issuance of new common stock for the Regulation A offering and the debt exchange.

Future Outlook

The company has secured an extension for its secured promissory note until September 30, 2026, providing additional time to manage its debt obligations. It also continues to raise capital through its Regulation A offering, with $6.7 million already secured, and has reduced other debt through equity conversion.

Management Comments

• The Company, by signing this No. 7 Amendment, hereby absolutely and unconditionally releases and forever discharges Lender and any and all of their parent companies, subsidiary companies, affiliated companies, insurers, indemnitors, successors and assigns together with all of their respective present and former managers, directors, officers, agents and employees from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which the Company has had, now has, or has made claim to have against any such party for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment, whether such claims, demands and causes of action are matured or unmatured or known or unknown.

Industry Context

na

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of 1,912,383 units in the Regulation A offering (including Series D Preferred Stock convertible to common) and 597,578 common shares for the debt exchange.
• Creditors (FRV): The maturity date of their loan has been extended, potentially delaying repayment but maintaining the 12% interest rate and secured status.
• Creditors (Unsecured Note Holder): Their debt has been reduced by $2,060,000 principal and $45,000 interest in exchange for equity.

Next Steps

• Continue to receive proceeds from the Regulation A Offering until the maximum amount is reached.
• Manage interest payments on the secured promissory note, with the next payment for accrued interest due on September 30, 2025, and all subsequent accrued interest due on September 30, 2026.
• Potentially exercise the option to repay parts of the secured promissory note early, in amounts no less than $50,000.

Key Dates

Recommendation

While the company successfully extended a key loan and raised capital, these actions are primarily defensive, aimed at managing existing debt and securing liquidity. The repeated loan extensions and high interest rate suggest underlying financial pressures. The significant dilution from both the Regulation A offering and the debt-for-equity exchange could weigh on per-share value. The company is addressing immediate financial needs, but the long-term outlook remains uncertain given the cost of capital and ongoing dilution. A 'hold' recommendation is appropriate as investors should monitor the company's ability to leverage the new capital for growth and reduce its reliance on high-cost debt, while being mindful of continued dilution.

Keywords

HeartSciences Inc., HSCS, SEC Filing, 8-K, Loan Agreement, Promissory Note, Debt Extension, Regulation A Offering, Capital Raise, Debt Exchange, Common Stock, Series D Preferred Stock, Warrants, Front Range Ventures, Financial Reporting, Corporate Finance